Vnitr Lek 2021, 67(3):165-168 | DOI: 10.36290/vnl.2021.038

Rivaroxaban for the treatment and prevention of reccurence of venous thromboembolism in children

Eliška Boženková, Miroslav Souček
II. interní klinika, Fakultní nemocnice u sv. Anny v Brně

Venous thromboembolism in children is rare, but the incidence has increased sharply during the last years. The standard of care for treating this disease consists of warfarin, unfractionated heparin, low-molecular-weight heparins and fondaparinux. Lately, the usage of rivaroxaban (direct oral anticoagulant) was officially approved. According to a recent study, treatment with rivaroxaban resulted in a similarly low recurrence risk and reduced thrombotic burden without increased risk of bleeding. The usage of direct oral anticoagulants could overcome the limitation of currently used care (mainly the necessity of regular laboratory monitoring and parenteral application) while providing similar efficacy and safety to treat venous thromboembolism in children.

Keywords: children, DOAC, rivaroxaban, thromboembolic disease, venous thromboembolism.

Published: May 26, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Boženková E, Souček M. Rivaroxaban for the treatment and prevention of reccurence of venous thromboembolism in children. Vnitr Lek. 2021;67(3):165-168. doi: 10.36290/vnl.2021.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Raffini L, Huang YS, Witmer C et al. Dramatic increase in venous thromboembolism in children's hospitals in the United States from 2001 to 2007. Pediatrics 2009; 124(4): 1001-1008. Go to original source... Go to PubMed...
    2. Mahajerin A, Croteau SE. Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. Front Pediatr 2017; 10(5): 68. Go to original source... Go to PubMed...
    3. Victoria T, Mong A, Altes T et al. Evaluation of pulmonary embolism in a pediatric population with high clinical suspicion. Pediatr Radiol 2009; 39(1): 35-41. Go to original source... Go to PubMed...
    4. Monagle P, Chan AKC, GoldenbergNA et al. Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl): 737S-801S. Go to original source...
    5. Sandoval JA, Sheehan MP, Stonerock CE et al. Incidence, risk factors, and treatment patterns for deep venous thrombosis in hospitalized children: an increasing population at risk. J Vasc Surg 2008; 47(4): 837-843. Go to original source... Go to PubMed...
    6. Chan AK, Monagle P. Updates in thrombosis in pediatrics: where are we after 20 years? Hematology Am Soc Hematol Educ Program 2012; 2012(1): 439-443. Go to original source... Go to PubMed...
    7. Raffini J, Scott JP. Thrombotic Disorders in Children. In: Kliegman RM, Geme JS. Nelson Textbook of Pediatrics. 21st ed. Elsevier: Philadelphia 2019: 2603-2067. ISBN: 978-0-323-52950-1
    8. Macartney CA, Chan AK. Thrombosis in children. Semin Thromb Hemost. 2011; 37(7): 763-771. Go to original source... Go to PubMed...
    9. Male C, Lensing AWA, Palumbo JS et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thrombembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol 2020; 7(1): 18-27. Go to original source... Go to PubMed...
    10. Hluší A, Slavík L, Palová M et al. Nová orální antikoagulancia - pohled hematologa. Interní Med. 2015; 17(4): 200-203.
    11. SPC - Souhrn údajů o přípravku. SÚKL. [cit. 2021-03-26]. Dostupné z WWW: https://www.ema.europa.eu/en/documents/product-information/pradaxa-epar-product-information_cs.pdf
    12. SPC - Souhrn údajů o přípravku. SÚKL. [cit. 2021-03-26]. Dostupné z WWW: https://www.ema.europa.eu/en/documents/product-information/xarelto-epar-product-information_cs.pdf
    13. Halton J, Brandao LR, Luciani M et al. Dabigatran etexilate for the treatment of acute venous thrombembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial. Lancet Haematol 2021; 8(1): 22-33. Go to original source... Go to PubMed...
    14. Van Ommen CH, Albisetti M, Chan AK et al. The Edoxaban Hokusai VTE PEDIATRICS Study: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease. Res Pract Thromb Haemost 2020; 4(5): 886-892. Go to original source... Go to PubMed...
    15. Apixaban for the acute treatment of venous thromboembolism in children. Pfizer. [cit. 2021-03-26]. Dostupné z WWW: https://www.pfizer.com/science/find-a-trial/nct02464969

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.